公开(公告)号：US07879334B1

公开(公告)日：2011-02-01

申请号：US11799442

申请日：2007-04-30

申请人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

发明人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

IPC分类号： C07K16/46 ,  A61K39/00 ,  A61K39/35 ,  A61K39/36

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

摘要翻译： 本发明涉及用于治疗IgE介导的过敏性病症和FcαRⅠ介导的自身免疫病症的双功能融合分子。 本发明提供了一种新的治疗方法，用于治疗由摄入，吸入，皮肤和肠胃外暴露于过敏原引起的急性和晚期过敏反应，包括哮喘，过敏性鼻炎，特应性皮炎，严重食物过敏，慢性荨麻疹和血管性水肿 ，以及由于诸如蜂刺或青霉素过敏等暴露引起的过敏反应。 此外，本发明提供了一种新颖，更安全和更有效的过敏疫苗形式。

公开(公告)号：US20110020373A1

公开(公告)日：2011-01-27

申请号：US12294852

申请日：2007-03-30

申请人： Andrew Saxon ,  Ke Zhang

发明人： Andrew Saxon ,  Ke Zhang

IPC分类号： A61K39/395 ,  A61P31/12 ,  A61P37/00 ,  A61P35/04

CPC分类号： C07K16/00 ,  A01K2267/03 ,  A61K39/00 ,  A61K47/6455 ,  A61K47/646 ,  A61K47/6807 ,  A61K47/6883 ,  A61K2039/53 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/80 ,  C12N15/87

摘要： This invention is directed to a novel approach for focusing and expressing DNA vaccinates in Antigen Presenting Cells (APCs) mediated through targeting IgE receptors (FcεRs) on APC and driving DNA expression through provision of an APC specific regulatory element This vaccine can be used in the prevention or treatment of allergic disease.

摘要翻译： 本发明涉及一种用于聚焦和表达在APC上通过靶向IgE受体介导的抗原呈递细胞（APC）中的DNA接种的新方法，并通过提供APC特异性调节元件驱动DNA表达。可以使用该疫苗 在预防或治疗过敏性疾病。

公开(公告)号：US07265208B2

公开(公告)日：2007-09-04

申请号：US09847208

申请日：2001-05-01

申请人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

发明人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

IPC分类号： C07K16/46 ,  C12P21/08

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

摘要翻译： 本发明涉及用于治疗IgE介导的过敏性病症和FcepsilonRI介导的自身免疫病症的双功能融合分子。 本发明提供了一种新的治疗方法，用于治疗由摄入，吸入，皮肤和肠胃外暴露于过敏原引起的急性和晚期过敏反应，包括哮喘，过敏性鼻炎，特应性皮炎，严重食物过敏，慢性荨麻疹和血管性水肿 ，以及由于诸如蜂刺或青霉素过敏等暴露引起的过敏反应。 此外，本发明提供了一种新颖，更安全和更有效的过敏疫苗形式。

公开(公告)号：US20120148585A1

公开(公告)日：2012-06-14

申请号：US12971888

申请日：2010-12-17

申请人： Andrew Saxon

发明人： Andrew Saxon

IPC分类号： A61K39/395 ,  C12N15/62 ,  C12N15/63 ,  A61P37/08 ,  C12N5/10 ,  C12N1/15 ,  C12N1/21 ,  C07K19/00 ,  C12N1/19

CPC分类号： C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.

摘要翻译： 本发明涉及双功能融合分子，以及用于治疗由过度或不需要的免疫应答引起的免疫疾病的新型，更安全和更有效的方法。 本发明提供抑制I型过敏（即IgE介导的）变态反应病症的方法，用于预防因过敏性和自身免疫性疾病的传统肽免疫治疗而发生的过敏反应的方法，并提供新的治疗方法 的自身免疫病症，其中方法降低了触发过敏反应的风险。 本发明提供了用于治疗过敏反应的新型治疗方法，包括预防由环境变应原暴露引起的过敏反应。 本发明还提供了治疗自身免疫性疾病如多发性硬化，自身免疫性I型糖尿病和类风湿性关节炎的方法。 本发明还提供了用于在传统抗原治疗期间预防过敏反应的方法。

公开(公告)号：US07534440B2

公开(公告)日：2009-05-19

申请号：US10000439

申请日：2001-10-24

申请人： Andrew Saxon

发明人： Andrew Saxon

IPC分类号： A61K39/00 ,  A61K38/16 ,  A61K38/17 ,  C07K14/00

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.

摘要翻译： 本发明涉及双功能融合分子，以及用于治疗由过度或不需要的免疫应答引起的免疫疾病的新型，更安全和更有效的方法。 本发明提供抑制I型过敏（即IgE介导的）变态反应病症的方法，用于预防因过敏性和自身免疫性疾病的传统肽免疫治疗而发生的过敏反应的方法，并提供新的治疗方法 的自身免疫病症，其中方法降低了触发过敏反应的风险。 本发明提供了用于治疗过敏反应的新型治疗方法，包括预防由环境变应原暴露引起的过敏反应。 本发明还提供了治疗自身免疫性疾病如多发性硬化，自身免疫性I型糖尿病和类风湿性关节炎的方法。 本发明还提供了用于在传统抗原治疗期间预防过敏反应的方法。

公开(公告)号：US07488804B2

公开(公告)日：2009-02-10

申请号：US11050113

申请日：2005-02-02

申请人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

发明人： Andrew Saxon ,  Ke Zhang ,  Daocheng Zhu

IPC分类号： C12P21/08

CPC分类号： C07K16/00 ,  C07K2317/52 ,  C07K2319/30 ,  Y10S530/866 ,  Y10S530/868

摘要： The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1 heavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

摘要翻译： 本发明包括融合分子，其包含Fcepsilon片段序列，其包含在其C末端至N末端连接的IgE重链（CHepsilon2-CHepsilon3-CHepsilon4序列）的恒定区的功能活性的CH 2，CH 3和CH 4结构域 包含IgG1重链恒定区的功能活性铰链，CH2和CH3结构域的第二多肽（gammahing-chgamma-2-CHgamma3序列），包含该融合分子的药物组合物和使用该融合分子的治疗方法。

公开(公告)号：US07879324B2

公开(公告)日：2011-02-01

申请号：US12404012

申请日：2009-03-13

申请人： Andrew Saxon

发明人： Andrew Saxon

IPC分类号： A61K39/00 ,  C07K16/46

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.

摘要翻译： 本发明涉及双功能融合分子，以及用于治疗由过度或不需要的免疫应答引起的免疫疾病的新型，更安全和更有效的方法。 本发明提供抑制I型过敏（即IgE介导的）变态反应病症的方法，用于预防因过敏性和自身免疫性疾病的传统肽免疫治疗而发生的过敏反应的方法，并提供新的治疗方法 的自身免疫病症，其中方法降低了触发过敏反应的风险。 本发明提供了用于治疗过敏反应的新型治疗方法，包括预防由环境变应原暴露引起的过敏反应。 本发明还提供了治疗自身免疫性疾病如多发性硬化，自身免疫性I型糖尿病和类风湿性关节炎的方法。 本发明还提供了用于在传统抗原治疗期间预防过敏反应的方法。

公开(公告)号：US20060154261A1

公开(公告)日：2006-07-13

申请号：US11031822

申请日：2005-01-07

申请人： Andrew Saxon ,  David-Diaz Sanchez ,  Frank Gilliland

发明人： Andrew Saxon ,  David-Diaz Sanchez ,  Frank Gilliland

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/142 ,  C12Q2600/156

摘要： The present invention is related generally to a method for screening subjects to determine those subjects more likely to exhibit a hypersensitivity to allergen in the presence of airborne pollutants, such subject having a GSTM1 null genotype and/or a GSTP1 Ile/Ile genotype. This invention also provides novel or improved pharmaceutical compositions and therapeutic strategies for the treatment of immune diseases resulting from inappropriate or unwanted immune response such as allergic reactions.

摘要翻译： 本发明一般涉及一种用于筛选受试者以确定那些在空气传播的污染物存在下对变应原过敏的受试者（具有GSTM1无效基因型和/或GSTP1Ile / Ile基因型）的受试者的方法。 本发明还提供了用于治疗由不适当或不期望的免疫应答如过敏反应引起的免疫疾病的新颖或改进的药物组合物和治疗策略。

公开(公告)号：US6030830A

公开(公告)日：2000-02-29

申请号：US911894

申请日：1997-08-15

申请人： Andrew Saxon ,  Ke Zhang ,  Shigeharu Fujieda

发明人： Andrew Saxon ,  Ke Zhang ,  Shigeharu Fujieda

IPC分类号： A61K38/00 ,  C07K16/00 ,  C12N15/113 ,  C12N15/11 ,  C07H21/04 ,  C12N15/63

CPC分类号： C12N15/113 ,  A61K38/00 ,  C12N2310/111

摘要： Compositions and methods for directing the synthesis of a particular human immunoglobulin isotype are provided. Nucleic acid molecules representing sense and antisense sequences of trans-spliced messenger ribonucleic acid molecules enhance or reduce, respectively, isotype recombination to IgE, IgA or IgG isotypes from an IgM isotype. Particular methods and compositions for the treatment of allergy and allergic reaction are described through inhibition of IgE.

摘要翻译： 提供用于指导特定人免疫球蛋白同种型合成的组合物和方法。 代表反式拼接信使核糖核酸分子的正义和反义序列的核酸分子分别增强或减少IgM同种型的IgE，IgA或IgG同种型的同种型重组。 通过抑制IgE来描述治疗过敏和过敏反应的具体方法和组合物。

公开(公告)号：US5552537A

公开(公告)日：1996-09-03

申请号：US37579

申请日：1993-03-24

申请人： Andrew Saxon ,  Ke Zhang ,  Edward E. Max

发明人： Andrew Saxon ,  Ke Zhang ,  Edward E. Max

IPC分类号： A61K38/00 ,  C07K16/00 ,  C07H21/04 ,  C07H21/02 ,  C12Q1/68

CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K2317/52

摘要： Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds which specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2", SEQ ID NO:02, residues 1-107 and, (SEQ. ID NO:06, CH4'-CH5-M1'-M2, (see SEQ ID NO:02, residues 1-72,SEQ ID NO:03 and SEQ ID NO:05) CH4'-CH5-M2'(SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:07 and CH4'-CH5-M2" (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:06). Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.

摘要翻译： 提供了关于新型IgE同种型及其在免疫超敏反应诊断和治疗中的应用的方法和组合物。 组合物包括免疫球蛋白ε位点的转录和翻译产物，ε转录产物的特异性探针和特异性结合ε翻译产物表位的化合物。 ε位点的新产物包括以下转录产物及其翻译产物：CH4-M2“，SEQ ID NO：02，残基1-107和（SEQ ID NO：06，CH4'-CH5-M1'- （参见SEQ ID NO：02，残基1-72，SEQ ID NO：03和SEQ ID NO：05）CH4'-CH5-M2'（SEQ ID NO：02，残基1-72，SEQ ID NO： 03和SEQ ID NO：07和CH4'-CH5-M2“（SEQ ID NO：02，残基1-72，SEQ ID NO：03和SEQ ID NO：06），这样的ε产物，特异性探针和结合化合物 用于免疫超敏反应诊断和治疗的方法和试剂盒。